Skip to content

Protocol · Nutritional Deficiency

Molybdenum Deficiency Protocol

No supplement has been shown to treat molybdenum deficiency. The molybdenum deficiency stack includes molybdenum alone, with no grade, because no trial has tested it in either form of the problem. The inherited form, molybdenum cofactor deficiency, starts in newborns: the body cannot build the cofactor, and early attempts to treat it with molybdate failed. Specialists treat its type A with fosdenopterin, a prescription medicine that improved survival in small company-funded studies; type B has no specific treatment. Deficiency from diet is very rare, and the one reported case suggesting it followed 12 months of feeding by vein without molybdenum. A newborn with seizures needs emergency care.

Sources: PMID 36296488; PMID 40132614; PMID 26343839; PMID 38187804

1 supplement studied for Molybdenum Deficiency. Each row gives the amount the protocol lists and the grade our evidence database holds for that supplement in Molybdenum Deficiency.

The stack

Amount listed in this protocol; not a recommendation.

Supplements in the Molybdenum Deficiency protocol, with the amount the protocol lists, the grade on file and confirmed studies
GradeSupplement and why it’s in the stackAmount listedEvidence on file
Not graded No supplement here has a grade: none has been tested in this condition
–MolybdenumNo grade: no trial has tested molybdenum in either form of the deficiency. Early molybdate treatment did not work in the inherited cofactor disorder; one person fed by vein for 12 months without molybdenum improved once it was added
  • Serum Molybdenum Levels: studied
  • Sulfite Levels: studied
  • Neurological Symptoms: studied
3 confirmed studies

Confirmed studies for Molybdenum (titles as PubMed lists them)

Amount listed: No amount: the inherited disorder needs specialist treatment and a shortage from diet is very rare, so any molybdenum is set by a clinician (source under Safety and when to see a clinician)Not graded yet

Outcomes studied: ▲ improves · ▼ worsens · ◆ changes; see studies.

What the evidence says

  • Shortage from diet. A 2023 scoping review prepared for the Nordic Nutrition Recommendations turned up no report of a healthy person showing clinical signs of a molybdenum shortage caused by diet, and noted that no biochemical marker shows a person's molybdenum status. It describes one case suggestive of deficiency, in a person with Crohn's disease fed entirely by vein for 12 months on a feed with no molybdenum: irritability, a fast heart rate, fast breathing and night blindness, with low blood methionine and uric acid. The symptoms improved on ammonium molybdate, and the blood and urine tests were normal again after 30 days. The original 1981 report calls this amino acid intolerance reversed by molybdate therapy. (PMID 38187804; PMID 6795919)
  • Low intake did not bring on deficiency in a controlled feeding study. Four young men ate a low-molybdenum diet for 102 days and then the same diet with added molybdenum for 18 days. On the low diet they could not always stay in balance, but balance improved over time and no signs of deficiency appeared; the body absorbed molybdenum efficiently at both intakes and turned it over more slowly when intake was low. (PMID 7733035)
  • The inherited form is a different disease. In molybdenum cofactor deficiency the body cannot assemble the cofactor its enzymes need; which building step fails sets the type (A, B or C), and the damage comes mainly from toxic sulfite, with brain scans that can look like injury from a shortage of oxygen. A natural history study of 58 patients (41 with type A, 17 with type B) found that 49 had their first symptoms within 28 days of birth, that seizures (60.3%) and feeding difficulties (53.4%) were the commonest first signs, that 77.4% were alive at 1 year, and that the median age at death was 2.4 years. (PMID 36296488; PMID 35192225)
  • Extra molybdenum does not correct the inherited form. A 2022 review notes that molybdate was tried early on to raise cofactor production and did not succeed. Laboratory work in cells from patients suggests molybdate could partly restore cofactor activity for a few rare gene variants (one type C case and some isolated sulfite oxidase variants), which the review presents as a possible future approach rather than current care. Diets that limit protein and sulfur amino acids have been used under specialist care in milder cases, lowering urine markers and, in some patients, steadying development; the review lists no specific treatment for type B or C. (PMID 36296488)
  • Type A is treated by replacing the missing building block, cyclic pyranopterin monophosphate (cPMP), given into a vein. In a Lancet cohort of 16 newborns treated under a compassionate-use programme (11 with type A, 5 with type B), urine disease markers returned to almost normal within 2 days in all type A patients, convulsions stopped or fell sharply in 8, and 3 treated early stayed seizure-free with near-normal development; type B showed no response. Comparing 14 treated patients with type A against 37 untreated ones from a natural history study, the risk of death was 5.1 times higher without treatment (95% CI 1.32 to 19.36), and at 12 months 43% of treated patients could sit unassisted, 44% could walk and 57% could feed by mouth; starting within 14 days of birth looked better than starting later. The US FDA approved the synthetic form, fosdenopterin, for type A in patients of any age, to lower their chance of dying, while a 2024 consensus guideline calls the evidence base for its use very limited. None of these comparisons is randomised: the survival result sets treated patients against untreated patients from a natural history study, and both studies had funding or authors from companies developing the treatment. (PMID 26343839; PMID 40132614; PMID 33909276; PMID 38627985)

Safety and when to see a clinician

  • Seizures in the first days of life, or very poor feeding, in a newborn need emergency care. This disorder is easily taken for brain damage from a lack of oxygen during birth; a review of 12 cases notes that most patients are misdiagnosed that way. Ask whether urine and blood tests for sulfite disorders (sulfite, S-sulfocysteine, xanthine and urate) have been done, because treatment for type A works best when it starts early. (PMID 23122324; PMID 35192225; PMID 40132614)
  • Do not give a baby molybdenum or any other supplement for this disorder: extra molybdenum did not correct it. A 2024 consensus guideline written by specialists in sulfite disorders sets out how these children are diagnosed and managed, and notes that survival and the quality of symptom care vary widely between them. (PMID 36296488; PMID 38627985)
  • Fosdenopterin is a prescription medicine given into a vein, not a supplement, and it has its own risks. In the three treatment studies combined in a 2025 analysis, 13 of 14 treated patients had an adverse event; most were judged unrelated to treatment and mild to moderate, and none led to stopping. Serious adverse events were common: 8 of 10, 7 of 8 and 2 of 2 patients in the three studies had at least one, most often catheter-related events and infections. Two patients on the earlier recombinant form died, one of a viral pneumonia judged unrelated and one of necrotising enterocolitis, a serious bowel illness judged possibly related. No skin reactions to light were seen, but the authors advise people on fosdenopterin to limit or avoid sun exposure. (PMID 40132614)
  • Extra molybdenum is not risk-free. Human data on molybdenum toxicity are scarce, but raised blood uric acid and gout-like symptoms have been reported where soil is high in molybdenum, and similar symptoms in people exposed to it at work; population studies also link high blood molybdenum with a faster fall in kidney filtration (glomerular filtration rate). The current upper limit rests on reproductive harm in rats that later studies did not repeat. A review of toxicity in humans links harm from molybdenum to copper: people who eat little copper or have a disorder of copper handling may be more at risk. Molybdate is added to some foods and supplements, so count every source before taking more. (PMID 38187804; PMID 10362269)
  • If you depend on long-term feeding by vein, ask your nutrition team to include molybdenum when they review trace elements. A systematic review of trace elements in adult intravenous feeding concluded that every such prescription should include a daily trace element dose at physiological levels, because a long shortfall can worsen symptoms or cause malnutrition syndromes. (PMID 27049031)

Safety note. Talk to a doctor or pharmacist before you start any of these if you take prescription medicines, are pregnant or breastfeeding, or have a long-term health condition. Supplements can interact with medicines.

Printed from winnowleaf.com/protocols/molybdenum-deficiency. For education only; not medical advice. Talk to a clinician before starting any supplement.